Clinical trials: Lymphangiomyomatosis
Chronic Respiratory Diseases, Cystic Fibrosis
Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases
Assessment of cardiovascular disorders using echocardiography and arterial stiffness; comparative noninvasive assessment of volatile organic compound (eVOC) exhale breath patterns in patients with different chronic respiratory…
- Conditions
- Chronic Respiratory Diseases, Cystic Fibrosis, Lymphangioleiomyomatosis, Hypersensitivity Pneumonitis
- Trial name
- NCT05727852
- Testing
- Breath test using the Compact PTR-TOF-MS, Portable cardiac monitor "CardioQvark", Assessment of arterial stiffness using the VaSera VS-1500N
- Where
- Russia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Lymphangioleiomyomatosis
Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial
RESULT is a phase II dose-escalating, open-label, safety and efficacy study to determine if there is a potential benefit of resveratrol in combination with sirolimus in patients with lymphangioleiomyomatosis (LAM).
- Trial name
- RESULT (NCT03253913)
- Testing
- Sirolimus, Resveratrol
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Cincinnati
Lymphangioleiomyomatosis
Effect of Loratadine in Lymphangioleiomyomatosis
INTRODUCTION: LAM is a rare and lethal disease characterized by progressive cystic lung destruction. Inhibition of mTOR with rapamycin is the current standard of care (SOC), which can slow-down disease.
- Trial name
- LORALAM (NCT05190627)
- Testing
- Loratadine
- Where
- 6 sites in Spain
- Volunteers
- 62 people
- Sponsor
- Institut d'Investigació Biomèdica de Bellvitge
Advanced Malignant Neoplasm, Castleman Disease
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body…
- Conditions
- Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease
- Trial name
- NCT01552434
- Testing
- Bevacizumab, Cetuximab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphangioleiomyomatosis (LAM), Lymphangioleiomyomatosis
Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease that appears to behave like a slowly growing cancer. Since clinical progression is very slow, new blood tests have been used to speed the time required to find safe and…
- Trial name
- LAMP-2 (NCT06889168)
- Testing
- Imatimib Mesylate
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Columbia University
Lymphangioleiomyomatosis
Characterizing LAM With 11C-Choline PET/CT
It was reported that TSC2-deficient cells enhance phosphatidylcholine synthesis via the Kennedy pathway. 11C-Choline can reflect the metabolic process of choline in vivo by intravenous injection.
- Trial name
- NCT05087134
- Testing
- 11C-Choline
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College Hospital
Lymphangioleiomyomatosis
LAM Pilot Study With Imatinib Mesylate
This is a phase 1 clinical trial comparing imatinib mesylate to placebo for individuals with lymphangioleiomyomatosis (LAM).
- Trial name
- LAMP-1 (NCT03131999)
- Testing
- Imatinib Mesylate 400Mg Capsule
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Medical University of South Carolina
Perivascular Epithelioid Cell Tumor, Malignant
Molecular Characterization of Perivascular Epithelioid Cell Tumors
Perivascular epithelioid cell tumors (PEComas) are rare and are characterized by the expression of myomelanocytic markers. They are a complex family that includes angiomyolipomas, lymphangioleiomyomatoses and other soft tissue…
- Trial name
- PEComesCells (NCT05617105)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Lymphangioleiomyomatosis, Sleep Disorder
Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis
Lymphangioleiomyomatosis (LAM) is a rare and progressive pulmonary disease of unknown etiology that almost exclusively affects women.
- Conditions
- Lymphangioleiomyomatosis, Sleep Disorder, Sleep Apnea Syndromes, Hypopnea Syndrome
- Trial name
- NCT04577937
- Testing
- LAM patients underwent PSG
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- dr. Stefano Nava
Lymphangioleiomyomatosis
Safety and Durability of Sirolimus for Treatment of LAM
The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of…
- Trial name
- MIDAS (NCT02432560)
- Testing
- Sirolimus, Everolimus
- Where
- 20 sites in United States
- Volunteers
- 600 people
- Sponsor
- University of Cincinnati
Pulmonary Function
A National Registry on Chinese Patients With Lymphangioleiomyomatosis
Pulmonary lymphangioleiomyomatosis (LAM), a disease characterized by diffuse cystic changes in the lung, is a rare disorder that affects almost exclusively women.
- Trial name
- NCT03193892
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Peking Union Medical College Hospital